The Joint Action on Personalised Cancer Medicine (JA PCM) is designed to build upon and collaborate with a wide range of existing, past, current, and future initiatives to maximize its impact and ensure sustainable outcomes. By leveraging the strengths and outputs of these initiatives, JA PCM aims to create a cohesive and integrated approach to personalised cancer medicine across Europe.
Key collaborations
- Building on Past and Current Initiatives:
- CAN.HEAL and PCM4EU: JA PCM will leverage guidelines, protocols, and best practices developed in these initiatives to enhance its framework and activities.
- JA EPAAC, JA CanCON, JARC, JA IPAAC, JA CraNE, JA JANE, JAPreventNCD: These joint actions have provided valuable insights and methodologies that JA PCM will integrate to strengthen its approach.
- Alignment with Parallel Activities:
- EUnetCCC, JANE-2, eCAN+, TEHDAS-2, ERNs, EUCAIM, IHI, ECHOS, CCI4EU, oncNGS, unCAN: JA PCM will align its activities with these ongoing initiatives to ensure coherence and avoid duplication of efforts.
- Digital Europe and EIT Health: These major EC programs offer opportunities for collaboration and integration of digital innovations in cancer care.
- Integration with EU-wide Programs:
- European Beating Cancer Plan (EBCP): As the EBCP enters its final phase, JA PCM will explore opportunities within the EBCP and the Mission on Cancer to align its objectives and integrate its outcomes.
- 1+ Million Genomes Initiative, Genome of Europe, EOSC4Cancer, EPPerMEd: These initiatives provide a framework for genomic data sharing and analysis that JA PCM will utilize to enhance its data-driven approaches.
- Future Collaborations:
- EU Cancer Prevention Consortium: JA PCM aims to contribute to the development of this consortium, ensuring that its outcomes are integrated into broader cancer prevention and care strategies.
- Partnership on Personalised Medicine: JA PCM will actively participate in this partnership to foster innovation and collaboration in personalised medicine.